Chief Executive Officer and Executive Board Member
Mark Beards, ACMA, is the Chief Executive Officer at UTILITY therapeutics, and serves as an Executive Director of the company. Mark has over 25 years’ experience in the life sciences and financial sectors within global organisations and early stage companies. Mark spent 11 years in various roles within Abbott Laboratories then GlaxoSmithKline, across various commercial and R&D functions, before joining McKinsey & Company as a management consultant focused on supporting senior pharmaceutical clients. He then moved to Goldman Sachs as Vice President and Head of European Healthcare Equity Research, before moving back into senior consulting roles at Charles River Associates (VP, Life Science Strategy), and KPMG (Director, Life Science Strategy).
Immediately prior to joining UTILITY, Mark was Corporate Development Director, then Group Chief Financial Officer and Executive Board Member of Celixir plc, a clinical stage biotechnology company focused on developing cellular therapies. Mark holds a BA (Hons) and MA in Mathematics from The Queen’s College, Oxford University, and is a fully qualified Chartered Management Accountant.
Paul Eckburg M.D.
Acting Chief Medical Officer
Paul Eckburg, MD, serves as Acting Chief Medical Officer at UTILITY therapeutics, and has worked in clinical research and anti-infective drug development for over 18 years. He has provided Phase 1-4 expertise to pharmaceutical companies since 2000, and was involved in the development of multiple approved anti-infective products such as anidulafungin (Eraxis®), doripenem (Doribax®), inhaled levofloxacin (Quinsair™), ceftaroline (Teflaro®), and ceftazidime-avibactam (Avycaz®).
Dr. Eckburg received his bachelor’s degree in cell and structural biology from the University of Illinois at Urbana-Champaign and his medical doctorate from Rush University. He completed his Internal Medicine residency and Infectious Diseases fellowship at Stanford University School of Medicine, where he continues to teach as an Adjunct Clinical Assistant Professor.
Dr. Lutz Wevelsiep
VP of Regulatory Affairs
Dr. Lutz Wevelsiep, Ph.D. is the Vice President of Regulatory Affairs at UTILITY therapeutics and has more than 25 years’ experience in international Regulatory Affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through to marketing authorization as well as particular expertise in anti-infectives. He has prepared and managed various health authority interactions with FDA, EMA and EU national agencies.
Lutz has spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®). Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.
Dr. Anne Santerre Henriksen
VP of Clinical Development
Dr. Anne Santerre Henriksen is the Vice President of Clinical Development at UTILITY therapeutics. Anne specialises in anti-infectives with more than 15 years’ experience in the pharmaceutical industry, spanning roles in medical affairs, research, clinical development, scientific communication and business development. Anne acts as a medical expert for Phase 1 and Phase 2 clinical trials, and has conducted extensive work on evaluation of microbiological data and microbiology expertise for both new antibiotics and existing products. She brings significant experience in the design of clinical trial for antibiotics and analysis of results.
Anne holds a Batchelor’s degree in Biotechnology and Microbiology, and a Ph.D in Microbiology, from Institut national des Sciences appliquées de Toulouse
Ole Skov is the Chair of UTILITY therapeutics. He has more than 30 years of experience in management and entrepreneurship. Since 2008, Mr. Skov has been an Independent Investor and recently entered into an investment partnership with the European Investment Fund. Previously Mr. Skov has been a Management Consultant at McKinsey & Co. from 1987-1994 and subsequently became Managing Partner at Accenture Financial Services from 1994-2007. Mr. Skov is an investor and board member in several companies including Adsidius and Clinical-Microbiomics. Mr. Skov holds a degree in Commerce from Copenhagen Business School and an MBA from IMD in Lausanne, Switzerland.
Morten Sommer is the co-founder of several biotech companies working within fields of drug development, industrial biotechnology and microbiome research. Morten is also a Professor and Scientific Director at the Technical University of Denmark with a lab of 20+ PhD’s and Post docs working primarily in the field of antibiotic resistance and the human microbiome. Morten is the inventor on 20+ issued patents, patent applications and author of scientific papers in journals such as Science, Cell and Nature. Dr. Sommer holds a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church. Dr. Sommer was named Top 10 under 40 on Genetic Engineering and Biotechnology News list of Biopharma Research and Business executives.
Rasmus Toft-Kehler is the CEO of AntibioTx and the co-founder and board member of multiple biotech companies. Prior to entering biotech, Rasmus worked with M&A (Goldman Sachs and Gudme Raaschou), management consulting (Booz Allen Hamilton), and as a board member of a family-owned enterprise until it was successfully sold in 2005. Rasmus holds a business degree from New York University and Copenhagen Business School and an executive degree from Harvard Business School. Rasmus is the inventor of 5+ patents and is currently completing a quantitative PhD on serial entrepreneurship. His research has been published in leading scientific and entrepreneurship journals such as Nature Reviews Microbiology and the Journal of Business Venturing. In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.